Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Iressa
Gefitinib is a targeted therapy drug used to treat certain types of non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR), a protein often mutated in NSCLC. By blocking EGFR activity, gefitinib can inhibit cancer cell growth and spread.
Gefitinib is used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations.
Interstitial Lung Disease: Gefitinib can cause interstitial lung disease (ILD), which can be fatal. Patients should be monitored for pulmonary symptoms indicative of ILD. Hepatotoxicity: Liver injury, including fatal liver failure, has been reported with gefitinib.
Outcome:
Decreased gefitinib effectiveness
Mechanism:
St. John's wort induces CYP3A4, increasing gefitinib metabolism.
Outcome:
Increased risk of bleeding
Mechanism:
Gefitinib may enhance the anticoagulant effect of warfarin.
Outcome:
Decreased gefitinib absorption
Mechanism:
Antacids can alter gastric pH, affecting drug absorption.
Most likely new formulation: Liquid formulation for easier administration (Year: 2025, 60% confidence)
Based on current usage trends and emerging clinical trial data, there is a 70% likelihood of expanded indications for gefitinib in other EGFR-mutant cancers within the next 5 years.
Antineoplastic Agent, Tyrosine Kinase Inhibitor
Quinazoline